Welcome to Vivet Therapeutics
Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases.
Vivet Therapeutics is focused on optimizing gene therapy through a partnership with the Fundacion para la Investigacion Medica Aplicada (FIMA) at the Centro de Investigación Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression.
Latest News
-
Vivet Therapeutics awarded with the Prix Galien MedStartup in New York Vivet Therapeutics is very pleased and proud to have won the Prix Galien MedStartup Award for “Best Collaboration For the Developing…
-
GATEWAY clinical trial for Wilson Disease has now its website Wilson Disease is a rare, progressive genetic disorder that causes excess copper to be stored in the body. Learn more…
-
VTX‐801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease VTX-801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease Paris, France and New York, NY, August…
-
Gene Therapy aims to be a one-time treatment that may stop or slow the progression of Wilson disease Learn how gene therapy aims to target the cause of Wilson disease by delivering a working ATP7B gene into cells. …
-
Congratulations to all Women in Gene Therapy and to Dr. Gloria González-Aseguinolaza our CSO @Vivet Therapeutics! Congratulations to all Women in Gene Therapy and to Dr. Gloria González-Aseguinolaza our CSO @Vivet Therapeutics!
-
Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s PFIC Gene Therapy Programs Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive…
-
Vivet and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for WD Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational…
.jpg)
-
Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease PARIS, France and…
-
Vivet’s lead program, VTX-801 for Wilson Disease, highlighted during Pfizer’s Investor Day September 15th 2020 Vivet Therapeutics’ lead program, VTX-801 for Wilson Disease, was highlighted during Pfizer’s Investor Day September 15th 2020. We are very…
-
Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation. PARIS, France June 1st, 2020,…
-
Happy to share the March 2020 Info Wilson newsletter from ABPWilson! Vivet is very happy to share the March 2020 Info Wilson newsletter from ABPWilson (L’Association Bernard Pépin pour la Maladie…
-
Vivet Announces Publication in Nature Communications of VTX-803 Preclinical Data Vivet Announces Publication in Nature Communications of Preclinical Data from VTX-803, Vivet’ novel therapeutic in development for the treatment of…
-
PFIZER SECURES EXCLUSIVE OPTION TO ACQUIRE GENE THERAPY COMPANY VIVET THERAPEUTICS PFIZER SECURES EXCLUSIVE OPTION TO ACQUIRE GENE THERAPY COMPANY VIVET THERAPEUTICS Pfizer and Vivet to collaborate on development of potential…
-
Vivet Therapeutics Appoints Eduardo Bravo as New Chairman of the Board PARIS, France June 12th, 2018, Vivet Therapeutics, a biotechnology company developing novel gene therapies for rare, inherited metabolic diseases today…
.png)
-
FierceBiotech names Vivet Therapeutics as one of its 2017 “Fierce 15” Biotech Companies PARIS, France September 28th, 2017, Vivet Therapeutics is proud to announce that it has been named by FierceBiotech as one…
-
Vivet’s First Gene Therapy Product, VTX 801 for Wilson’s Disease, Receives EU and US ODD PARIS, France September 26th, 2017, Vivet Therapeutics, announced today that both the Food and Drug Administration (FDA) and the European…
-
FDA news : Cellular & Gene Therapy Guidances A useful resource of Cellular & Gene Therapy Guidance Documents
-
EMA News This section of the website provides information for companies and individuals involved in developing and marketing medicines for human use…
-
Gene Therapy of Liver Diseases In Europe, a disease is defined as rare when it affects fewer than one out of every 2,000 people. However,…
-
Vivet Therapeutics raises €37.5 million in Series A financing round Vivet Therapeutics raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases
